The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

Fatty liver disease occurs when more than 5-10% of the liver's weight is made up of fat. This can lead to inflammation in the ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) is expected to issue its quarterly earnings data before the market ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Theratechnologies Inc.’s THTX share price has surged by 20.78%, which has investors questioning if this is right time to sell ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

However, steatosis can progress to nonalcoholic steatohepatitis (NASH) in which case the liver is inflamed and compromised as in alcoholic related steatohepatitis (ASH). Symptoms can include pain ...